# CD300A

## Overview
The CD300A gene encodes the CD300a protein, a type I transmembrane glycoprotein that functions as an inhibitory receptor within the immune system. This protein is characterized by its immunoglobulin V-like (IgV-like) extracellular domain, which is part of the immunoglobulin superfamily, and is involved in ligand binding. The CD300a protein is primarily expressed on myeloid and some lymphoid cells, where it plays a critical role in modulating immune responses. It achieves this by binding to phosphatidylserine and phosphatidylethanolamine on apoptotic and activated cells, thereby maintaining immune homeostasis and preventing excessive inflammation. The protein's cytoplasmic tail contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which, upon phosphorylation, recruit phosphatases such as SHP-1 and SHP-2 to deactivate pro-inflammatory signaling pathways. This regulatory function is crucial in processes like phagocytosis and cytokine production, and it has significant implications in preventing autoimmunity and controlling inflammatory responses (Clark2009The; Gasiorowski2013CD300; Zenarruzabeitia2015The).

## Structure
The CD300A protein is a type I transmembrane glycoprotein characterized by a single immunoglobulin V-like (IgV-like) extracellular domain. This domain is part of the immunoglobulin superfamily and is involved in ligand binding (Lankry2010Expression; Clark2009The). The protein's structure includes a membrane proximal region, a transmembrane region, and a cytoplasmic tail. The cytoplasmic tail is notable for containing multiple immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which are crucial for its inhibitory signaling function (Lankry2010Expression; DeBell2012Functional).

The CD300A protein's cytoplasmic tail includes four tyrosine residues, three of which are within classical ITIM sequences, and one in a nonclassical ITIM. These motifs are phosphorylated by Src family kinases, such as Lck, and serve as docking sites for phosphatases like SHP-1 and SHP-2, which mediate the inhibitory signaling (Zenarruzabeitia2015The; DeBell2012Functional). The phosphorylation of these ITIMs is a common post-translational modification essential for the protein's function (DeBell2012Functional).

The CD300A protein can form homo- and heterodimers with other CD300 family members, adding complexity to its signaling pathways (Gasiorowski2013CD300). However, specific details on the primary, secondary, tertiary, or quaternary structure of CD300A are not provided in the available context.

## Function
The CD300A gene encodes the CD300a protein, an inhibitory receptor expressed on various immune cells, including myeloid and some lymphoid cells. CD300a plays a crucial role in modulating immune responses by binding to phosphatidylserine and phosphatidylethanolamine, which are exposed on the outer leaflet of apoptotic and activated cells. This binding is essential for recognizing apoptotic cells and modulating immune functions to maintain homeostasis and prevent excessive inflammation (Gasiorowski2013CD300; Zenarruzabeitia2015The).

CD300a contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain, which are phosphorylated upon activation. This phosphorylation recruits SH2 domain-containing phosphatases such as SHP-1 and SHP-2, leading to the deactivation of signaling pathways that would otherwise promote inflammation (Lankry2010Expression; Alvarez2008The). The receptor is involved in inhibiting processes like phagocytosis and cytokine production, thereby regulating immune cell functions and maintaining a balance between activation and inhibition (Clark2009The; Gasiorowski2013CD300).

CD300a is active primarily in the cell membrane and influences various cellular processes, including the modulation of dendritic cell functions, antigen presentation, and the regulation of leukocyte responses (Gasiorowski2013CD300). Its role in immune regulation is significant in preventing autoimmunity and controlling inflammatory responses.

## Clinical Significance
Alterations in the expression or function of the CD300A gene have significant clinical implications, particularly in the context of cancer and immune regulation. In melanoma, CD300A plays a crucial role in modulating tumor immunity. Higher expression levels of CD300A are associated with decreased numbers of tumor-infiltrating regulatory T (Treg) cells, which are known to suppress anti-tumor immune responses. This reduction in Treg cells correlates with longer survival times in melanoma patients, suggesting that CD300A expression may suppress tumor development by inhibiting Treg cell activation (Nakazawa2020Tumorderived).

CD300A also interacts with tumor-derived extracellular vesicles (TEVs), which can influence immune signaling pathways. The receptor is involved in inhibiting TLR3-mediated signaling for interferon-beta production, a process that affects Treg cell proliferation and survival. This interaction highlights the potential of CD300A to modulate immune responses within the tumor microenvironment, impacting tumor progression and patient outcomes (Nakazawa2020Tumorderived).

In addition to its role in cancer, CD300A is implicated in thrombo-inflammatory diseases through its interaction with CD148, a transmembrane tyrosine phosphatase. This interaction may influence inflammatory cytokine and chemokine production, further underscoring the receptor's role in immune response regulation (Barroso2021AVEXIS).

## Interactions
CD300A, also known as CD300a, is an inhibitory receptor that participates in various protein interactions crucial for its function in immune regulation. It contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic tail, which, upon phosphorylation by src family kinases like Lck, create docking sites for SH2 domain-containing proteins. These include the protein tyrosine phosphatases SHP-1 and SHP-2, which are recruited to the phosphorylated ITIMs of CD300A. SHP-1 is particularly essential for CD300A's inhibitory function, as its absence significantly reduces the receptor's ability to mediate inhibition (Zenarruzabeitia2015The; DeBell2012Functional).

CD300A also interacts with phosphatidylserine (PS) on apoptotic cells, facilitating the recruitment of SHP-1, which is crucial for its inhibitory signaling in mast cells and macrophages (NakahashiOda2012Apoptotic). In addition, CD300A has been identified to interact with CD148, a transmembrane tyrosine phosphatase, in platelets, highlighting its role in modulating immune responses (Barroso2021AVEXIS). These interactions underscore CD300A's role in immune regulation by modulating signaling pathways through its association with phosphatases and other proteins.


## References


[1. (Lankry2010Expression) Dikla Lankry, Hrvoje Simic, Yair Klieger, Francesca Levi-Schaffer, Stipan Jonjic, and Ofer Mandelboim. Expression and function of cd300 in nk cells. The Journal of Immunology, 185(5):2877–2886, September 2010. URL: http://dx.doi.org/10.4049/jimmunol.0903347, doi:10.4049/jimmunol.0903347. This article has 49 citations.](https://doi.org/10.4049/jimmunol.0903347)

[2. (Clark2009The) Georgina J. Clark, Xinsheng Ju, Courtney Tate, and Derek N.J. Hart. The cd300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends in Immunology, 30(5):209–217, May 2009. URL: http://dx.doi.org/10.1016/j.it.2009.02.003, doi:10.1016/j.it.2009.02.003. This article has 97 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.it.2009.02.003)

[3. (NakahashiOda2012Apoptotic) Chigusa Nakahashi-Oda, Satoko Tahara-Hanaoka, Masamichi Shoji, Yasushi Okoshi, Takako Nakano-Yokomizo, Nobuhiro Ohkohchi, Teruhito Yasui, Hitoshi Kikutani, Shin-ichiro Honda, Kazuko Shibuya, Shigekazu Nagata, and Akira Shibuya. Apoptotic cells suppress mast cell inflammatory responses via the cd300a immunoreceptor. Journal of Experimental Medicine, 209(8):1493–1503, July 2012. URL: http://dx.doi.org/10.1084/jem.20120096, doi:10.1084/jem.20120096. This article has 66 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1084/jem.20120096)

[4. (Zenarruzabeitia2015The) Olatz Zenarruzabeitia, Joana Vitallé, Cristina Eguizabal, Venkateswara R. Simhadri, and Francisco Borrego. The biology and disease relevance of cd300a, an inhibitory receptor for phosphatidylserine and phosphatidylethanolamine. The Journal of Immunology, 194(11):5053–5060, June 2015. URL: http://dx.doi.org/10.4049/jimmunol.1500304, doi:10.4049/jimmunol.1500304. This article has 81 citations.](https://doi.org/10.4049/jimmunol.1500304)

[5. (Gasiorowski2013CD300) Robin E. Gasiorowski, Xinsheng Ju, Derek N.J. Hart, and Georgina J. Clark. Cd300 molecule regulation of human dendritic cell functions. Immunology Letters, 149(1–2):93–100, January 2013. URL: http://dx.doi.org/10.1016/j.imlet.2012.10.005, doi:10.1016/j.imlet.2012.10.005. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.imlet.2012.10.005)

6. (Nakazawa2020Tumorderived) Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. This article has 0 citations.

[7. (Alvarez2008The) Yelina Alvarez, Xiaobin Tang, John E. Coligan, and Francisco Borrego. The cd300a (irp60) inhibitory receptor is rapidly up-regulated on human neutrophils in response to inflammatory stimuli and modulates cd32a (fcγriia) mediated signaling. Molecular Immunology, 45(1):253–258, January 2008. URL: http://dx.doi.org/10.1016/j.molimm.2007.05.006, doi:10.1016/j.molimm.2007.05.006. This article has 61 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.molimm.2007.05.006)

[8. (DeBell2012Functional) Karen E DeBell, Venkateswara R Simhadri, John L Mariano, and Francisco Borrego. Functional requirements for inhibitory signal transmission by the immunomodulatory receptor cd300a. BMC Immunology, April 2012. URL: http://dx.doi.org/10.1186/1471-2172-13-23, doi:10.1186/1471-2172-13-23. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2172-13-23)

[9. (Barroso2021AVEXIS) Ruben Barroso, Roy Bicknell, George Ed Rainger, Steve P. Watson, and Yi Sun. Avexis technology identifies novel platelet-leukocyte binding partners including cd148-cd300a. Blood Advances, 5(23):5016–5019, December 2021. URL: http://dx.doi.org/10.1182/bloodadvances.2021004546, doi:10.1182/bloodadvances.2021004546. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1182/bloodadvances.2021004546)